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Introduction
Low-dose aspirin is widely used for prevention of stroke,
heart attacks, and death in patients with atherothrom-
botic disease. In a survey conducted by Wood et al, it
was found that among 29.3% of patients who were suf-
fering from ≥ 1 macrovascular complications (ischemic
heart disease, cerebrovascular disease or peripheral vas-
cular disease), 63% were on aspirin treatment.1 A meta-
analysis which included the European Stroke Prevention
Study 2 trial found an overall 13% risk reduction in
vascular morbidity and mortality among patients receiv-
ing aspirin therapy.2 In another meta-analysis of low-
dose aspirin for secondary cardiovascular prevention,
aspirin reduced both the reinfarction and mortality
rates.3 The American Heart Association has extended
the indications for aspirin to the primary prevention
of cardiovascular events in anyone with a calculated
10-year cardiovascular risk of ≥ 10%.4 However, the use
of aspirin is associated with potentially serious gastroin-
testinal (GI) adverse effects. It has been estimated
that low-dose aspirin prevents 2–3 recurrent strokes
at the expense of 1 extra episode of GI bleeding per
year.3,5 With the increasing use of aspirin for cardio-
vascular protection, the incidence of GI complications
can be expected to increase in the near future. Various
strategies have been used to reduce aspirin-related GI
injury. One approach is to co-administer gastropro-
tective drugs (GPDs) with aspirin. The most common
classes of gastroprotective agent used in our hospital
were antacids and H2-receptor antagonists.6 The use
of antacids and H2-receptor antagonists as GPDs is
probably not confined to our hospital alone but
appears to be widespread among other hospitals.7–9
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This practice, however, is not consistent with exist-
ing evidence, as only misoprostol and proton pump
inhibitor (PPI) have been proven to reduce the
incidence of nonsteroidal anti-inflammatory drug
(NSAID)-induced peptic ulcers.10–13 Antacids may
afford some symptomatic relief, but offers no protec-
tion against aspirin-induced GI complications.7–9 Due
to the problems related to the utilization of GPDs
with low-dose aspirin, the prescription pattern of gas-
troprotective medications associated with low-dose
aspirin therapy needs to be evaluated. The aim of this
study was therefore to determine the prescription pat-
tern of GPDs with low-dose aspirin therapy.
Methods
This retrospective study was conducted at Tung Wah
Hospital, Hong Kong. This is one of the major hospi-
tals in western Hong Kong, and serves a population
of about 0.6 million. A computerized search of dis-
pensing records was used to identify patients who had
attended general and specialist outpatient clinics of
Tung Wah Hospital between September 1, 2007 and
September 30, 2007. The medical records of recruited
patients were obtained from the Medical Records
Department for further investigation. Patients were
included in the analysis if they were over the age of 18
and had received low-dose aspirin (< 300 mg daily)
for a minimum of 3 months. Patients with incomplete
medical record or who had used aspirin externally
(gargle) were excluded from the study.
Data were collected through retrospective chart
review by the investigator, and recorded on a standard-
ized data collection form. Continuous and categorical
data were expressed as mean and counts, respectively.
Univariate analysis was performed using χ2 tests for
discrete variables. A difference with a p value <0.05 was
considered significant. A multiple logistic regression
model was developed to identify factors that might be
associated with prescription of GPDs with low-dose
aspirin. The adequacy of model fit was assessed by
Hosmer-Lemeshow χ2 tests. All data were analyzed
using SPSS version 11.0 (SPSS Inc., Chicago, IL, USA)
for Windows. This study was approved by the institu-
tional review board of the University of Hong Kong.
On the data collection form, GI risk factors were
defined as: (1) age ≥ 65 years; (2) previous clinical
history of gastroduodenal ulcer, GI bleeding or
gastroduodenal perforation; (3) concomitant use of
medications that are known to increase upper GI adverse
events, e.g. corticosteroids and anticoagulants; (4) pres-
ence of serious comorbidity such as cardiovascular
disease, renal or hepatic impairment, diabetes and
hypertension.14
Results
During the period September 1 to September 30,
2007, 311 patients presented prescriptions for aspirin
to the pharmacy, of which 303 patients were included
in the study. Of the 8 patients who were excluded
from the study, 4 had incomplete medical records, 
2 used aspirin for duration < 2 weeks, and 2 used aspi-
rin externally as gargles. The main characteristics of
the patients are summarized in Table 1. Patient age
ranged from 37 to 95 years, with a mean ± standard
deviation of 72±10 years. Female subjects were slightly
older than male patients (74.2 years vs. 70.0 years,
p < 0.001). No sex difference was observed for the
concomitant medications, GPD co-prescription rate,
and clinical settings. More female patients presented
with concomitant diabetes mellitus than male patients
(52.6% vs. 31.5%, p < 0.001). Compared with female
patients, more male subjects had previous history of
peptic ulcer/GI bleeding (17.9% vs. 4.4%, p < 0.001).
No differences were found among other concomitant
diseases between female and male patients. All of the
303 patients had ≥ 1 GI risk factors, which identified
them as patients at high risk of developing aspirin-
associated complications, and most of them (81.5%)
had ≥ 2 GI risk factors. The rate of GPD prescription
was 48.5%. Most of the patients received H2-receptor
antagonist, and, to a lesser degree, antacid and PPI.
Univariate analysis
Factors that might be associated with the decision to
co-prescribe aspirin and GPD were separated into 3
groups: those related to patients’ demographic char-
acteristics, those related to patients’ clinical conditions,
and those related to clinical setting. Results of the uni-
variate analysis are shown in Table 1. The mean ages
of patients with and without GPD co-prescription
were 72.5 and 71.2 years, respectively. Previous his-
tory of gastroduodenal ulcer/bleeding, renal impair-
ment and hypercholesterolemia, presence of GI risk
factor, and clinical setting were significant determi-
nants of GPD co-prescription. Patients with docu-
mented prior history of GI diseases were more likely
to receive GPDs (23.8%), whereas those without GI
problems were less likely to (0.6%). In patients with
renal impairment, 15% were co-prescribed GPDs
compared with 6.4% of patients with normal renal
function. Patients managed in specialist clinics were
associated with a high prescription rate of GPDs.
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Patients with > 2 risk factors were more likely to be
co-prescribed a GPD.
Multivariate analysis
In the multivariate analysis (Table 2), only previous
history of gastroduodenal ulcer/bleeding and clinical
setting were significant determinants of GPD co-
prescription (Hosmer-Lemeshow χ2, 3.37; degrees of
freedom, 6; p = 0.761). After adjustment, hypercho-
lesterolemia, renal impairment, and GI risk factors
were no longer predictors of GPD use. As expected,
previous history of gastroduodenal ulcer/bleeding
significantly influenced the use of GPD. Patients with
history of GI ulcer/bleeding were much more likely
to be co-prescribed a GPD than those who had no
history of GI disorders (OR, 26.5). Compared with
patients who were managed in general outpatient clinic,
those managed in specialist clinic were more likely to
receive GPD (OR, 3.04).
Discussion
The aim of the present study was to determine the preva-
lence of concomitant use of GPD with low-dose aspirin
and the potential factors associated with co-prescription.
Risk factors for GI complications were very com-
mon among aspirin users in the present study. Overall,
all patients had at least 1 risk factor, and 81.5% had ≥ 2
risk factors. Such an observation is consistent with the
results of the study of Targownik and Al-Mamfud.15
They reported that 78% of aspirin users had at least 
Table 1. Demographic characteristics and univariate analysis*
With gastroprotection No gastroprotection 
p
(n = 147) (n = 156)
Age group (yr)
< 45 1 (0.7) 2 (1.3)
45–64 30 (20.4) 31 (19.9)
≥ 65 116 (78.9) 123 (78.8) 0.87
Sex
Male 87 (59.2) 81 (51.9) 0.20
Smoking habits
Smoker 24 (16.3) 22 (14.1)
Non-smoker 115 (78.2) 117 (75.0)
Unknown 8 (5.5) 17 (10.9) 0.21
Drinking habits
Drinker 13 (8.8) 12 (7.7)
Non-drinker 122 (83.0) 121 (77.6)
Unknown 12 (8.2) 23 (14.7) 0.20
Concomitant diseases
Hypertension 126 (85.7) 147 (92.9) 0.06
Hypercholesterolemia 51 (34.7) 73 (46.8) 0.04
Diabetes mellitus 57 (38.8) 67 (42.9) 0.46
Osteoarthritis 5 (3.4) 4 (2.6) 0.67
History of GD ulcer/bleeding 35 (23.8) 1 (0.6) < 0.001
Renal impairment 22 (15.0) 10 (6.4) 0.02
GI risk factors (n)
1 23 (15.6) 33 (21.2)
2 94 (63.9) 21 (77.6)
3 30 (20.5) 2 (1.2) < 0.001
Concomitant medications
Antiplatelet 2 (1.4) 2 (1.3) 0.30
Anticoagulant 1 (0.7) 0 (0) 0.95
Gastroprotective drug prescription 147 (96.6) 138 (88.5) 0.01
Clinical setting
Specialist clinic 142 (96.6) 138 (88.5) 0.01
*Data presented as n (%). GD = gastroduodenal; GI = gastrointestinal.
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1 risk, in addition to cardiovascular disease, and 15%
had ≥ 3 risk factors.
Despite high prevalence of GI risk factors, the pre-
scription rate of GPDs among aspirin users was low in
this study. Overall, 48.5% of patients received concomi-
tant GPD, and the prescription rate of GPD among pa-
tients with a history of gastroduodenal ulcer/bleeding
or with ≥ 2 risk factors for GI complications was 50.2%.
The American College of Rheumatology guidelines
recommend that patients with at least 1 GI risk factor
should receive either an NSAID plus a co-prescribed
protective agent or a COX-2 inhibitor,16 as do the
NICE (National Institute for Clinical Excellence) guide-
lines.14 However, these guidelines apply to NSAID
for treatment of rheumatoid arthritis or osteoarthritis.
Although aspirin is considered to be an NSAID, the
absolute risk of GI complications for low-dose aspirin
users is likely to be lower than that for NSAID users.
Targownik and Al-Mamfud recommend that GPDs
should be used in aspirin users with a history of gas-
troduodenal ulcer/bleeding, or in patients with ≥ 2 risk
factors for GI complications, of which 1 of the risk fac-
tors may be established cardiovascular disease.15 There-
fore, the percentage of appropriate treatment, 50.2%,
was in accordance with Targownik and Al-Mamfud’s
recommendation. The prescription rate of GPDs in this
study is relatively higher when compared to similar stud-
ies by other investigators. In the study by Targownik
and Al-Mamfud, it was found that only 24% of aspirin
users were discharged on appropriate GPDs.15 A Dutch
study reported that only 14% of elderly patients tak-
ing NSAIDs were prophylactically prescribed an H2-
receptor antagonist, PPI or misoprostol.17 In a national
veterans affairs survey, 27.2% of patients received ther-
apy appropriate to GI risk factors.18 More recently, 
a U.S. study demonstrated that among patients at risk
for NSAID-induced GI adverse events, only 26% were
receiving prophylactic treatment.19 Taken together,
these results indicate that the majority of patients
treated with aspirin/NSAIDs who would benefit from
protective therapies are not being appropriately treated.
The problem of underutilization of GPDs is not
unique to Hong Kong but also occurs in North America
and Europe and may be due to several reasons.20–22
Firstly, there may be a belief that low-dose aspirin
is safe and can be used for high-risk patients without
protective measures. However, aspirin is able to inhibit
prostaglandin synthesis even at doses as low as 10 mg/
day.23 In a meta-analysis by Derry and Loke, the pooled
odds ratio for bleeding with aspirin was 1.68.5 More
recently, a meta-analysis of 14 trials showed that the re-
lative risk of major GI bleeding with the use of low-dose
aspirin as compared with placebo was 2.07.24 A large
5-year observational cohort study from Denmark also
showed that the annual incidence of hospitalization
for upper GI bleeding was 0.60% for low-dose aspirin
users.25 In summary, meta-analyses as well as observa-
tional studies indicate that low-dose aspirin approxi-
mately doubles the risk of major GI bleeding and is
actually not as safe as expected.
Secondly, since the aspirin used in our hospital is
enteric-coated, there may be a misbelief that this for-
mulation is relatively safe. In a survey by Chey et al 
of perceptions of primary care physicians regarding
aspirin-associated toxicity, it was found that more than
half (53%) thought enteric-coated or buffered aspirin
reduced the risk of upper GI bleeding.26 However, cur-
rent evidence suggests that enteric-coating or buffer-
ing of aspirin does not reduce the risk of upper GI
bleeding.27
Thirdly, numerous guidelines on the proper use of
gastroprotective strategies for chronic NSAID users
have been published, but there are no similar guidelines
for low-dose aspirin users.14,16 The lack of official guide-
lines may lead to the underutilization of GPDs among
low-dose aspirin users. Although the absolute risk of GI
Table 2. Multivariate analysis of determinants of gastroprotective drugs co-prescription
Odds ratio 95% confidence interval p
Hypertension 0.489 0.214–1.109 0.087
Hypercholesterolemia 0.703 0.422–1.173 0.177
Previous history of GI ulcer/bleeding 26.493 2.565–273.60 0.006
Renal impairment 2.21 0.960–5.094 0.062
Clinical setting 3.04 1.001–9.206 0.049
GI risk factors (n)
1 1
2 1.105 0.595–2.051 0.752
3 2.493 0.357–17.399 0.357
GI = gastrointestinal.
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complications for low-dose aspirin is likely to be lower
than for NSAID users, low-dose aspirin is still associ-
ated with serious GI complications.15,24,25,28 Therefore,
it is not justified to provide no protective strategies for
a patient who is at risk of aspirin-related complications.
Fourthly, the benefits of GPDs in low-dose aspirin
users may be underappreciated, as there have been few
trials where gastroprotection strategies have been used
with low-dose aspirin.15 However, the efficacy of GPDs
in low-dose aspirin users has recently been proven in
2 Hong Kong studies. They showed that PPIs effec-
tively reduce aspirin-associated GI adverse events.29,30
Lastly, there may be a lack of knowledge about
risk factors related to aspirin-induced GI toxicity. It is
possible that physicians have insufficient knowledge
about different risk factors and thus do not routinely
evaluate whether aspirin users are at risk for develop-
ing aspirin-associated GI adverse events. This is sup-
ported by our findings as well as Erdeljic et al’s, which
demonstrated that the number of risk factors did not
increase the odds of GPD prescriptions in the multi-
variate analysis.31
Although the co-prescription rate of GPDs in the
present study was relatively high compared to that in
similar studies, when recommended classes of GPDs
were taken into consideration, the actual prevalence
of gastroprotection was unacceptably low (6.3%). 
H2-receptor antagonists was the most used (64.6%)
and, to a lesser degree, antacids (22.4%) and PPIs
(13.0%), and no patients received prostaglandin ana-
log. Obviously, the pattern of GPD use was not consis-
tent with current evidence. Currently, 4 classes of drugs,
namely PPI, prostaglandin analog, H2-receptor antag-
onist and antacid, are available for co-therapy with
NSAID, but only PPI and prostaglandin analog have
been shown to be effective at preventing NSAID-
associated gastric and duodenal ulcers.10–13 Further-
more, only misoprostol at a dose of 800 μg/day has
been demonstrated to reduce the risk of ulcer compli-
cations.32 There is evidence from randomized con-
trolled trials that double-dose H2-receptor antagonist
(e.g. famotidine 40 mg twice daily, or ranitidine 300mg
twice daily) reduces the incidence of both endoscopic
duodenal and gastric ulcers compared with placebo.33,34
However, there is no clinical outcome study to show
whether high doses prevent ulcer complications. Taken
together, the available data show that of all the possible
GPDs, only 2 classes are acceptable: PPI and prosta-
glandin analog. The use of double-dose H2-receptor
antagonist is controversial and thus not recommended.
Standard-dose H2-receptor antagonist and antacid
are not considered appropriate treatment in NSAID-
induced ulcer prophylaxis. These drugs may provide
patients with a false sense of security when they are
still exposed to a real risk. In fact, antacid and H2-
receptor antagonist can double the risk of serious GI
events by dangerously masking symptoms of GI irrita-
tion.7,35,36 Interestingly, no patients in our study re-
ceived misoprostol, and this result is comparable to
those of studies conducted in Europe.37 The reason for
this is probably related to its unfavorable tolerability
profile and inconvenient dosing schedule.32 So, our
study revealed a lack of knowledge among physicians
about the details of preventive strategies, especially with
regard to efficacy and appropriate regimens.
In multivariate analysis, a variety of factors that
significantly influenced the use of GPDs were identi-
fied. Among the various risk factors for upper gastro-
duodenal damage in patients receiving low-dose aspirin
therapy, only previous history of gastroduodenal
ulcer/bleeding was identified as a significant factor
associated with the co-prescription of GPDs. Patients
with history of gastroduodenal ulcer/bleeding were
much more likely to be co-prescribed a GPD. These
results indicate that physicians were aware of previous
history of gastroduodenal ulcer/bleeding as a risk
factor for aspirin-related GI adverse events but had
insufficient knowledge about other risk factors related
to increased risk.
Clinical setting was another significant determi-
nant of GPD co-prescription. Patients treated at spe-
cialist clinics had a greater likelihood of receiving a
GPD (OR, 3.04) than those treated at general outpa-
tient clinics. This is probably due to pharmacy formu-
lary restriction in which PPI is not available in general
outpatient clinic formulary. It could also be possible
that the most severe patients, as would be expected,
were managed in specialist clinics.
There are some limitations to our study. This was
a retrospective study, and data were collected through
chart review. The accuracy and completeness of data
collection depended on documentation by physicians.
Incomplete or poor documentation might have caused
incorrect or missing data in the medical records, thus
resulting in inaccurate data collection.
In conclusion, the prescription pattern of GPDs in
low-dose aspirin users was not consistent with litera-
ture recommendations, and this indicates the need for 
further educational measures.
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